AR083044A1 - Anticuerpos anti-cd48 y usos de los mismos - Google Patents

Anticuerpos anti-cd48 y usos de los mismos

Info

Publication number
AR083044A1
AR083044A1 ARP110103412A ARP110103412A AR083044A1 AR 083044 A1 AR083044 A1 AR 083044A1 AR P110103412 A ARP110103412 A AR P110103412A AR P110103412 A ARP110103412 A AR P110103412A AR 083044 A1 AR083044 A1 AR 083044A1
Authority
AR
Argentina
Prior art keywords
antibodies
bind
treatment
certain embodiments
same
Prior art date
Application number
ARP110103412A
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45870888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083044(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR083044A1 publication Critical patent/AR083044A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente solicitud proporciona anticuerpos que se unen a CD48 y métodos de uso de los mismos. De acuerdo con ciertas realizaciones, los anticuerpos son anticuerpos completamente humanos que se unen a CD48 humano. En ciertas realizaciones, los anticuerpos divulgados bloquean la unión de CD48 a uno o más receptores de CD48. Los anticuerpos son útiles, para el tratamiento de enfermedades y trastornos asociados a una o más actividades biológicas de CD48, que incluyen el tratamiento de afecciones alérgicas y otras afecciones inflamatorias.
ARP110103412A 2010-09-27 2011-09-19 Anticuerpos anti-cd48 y usos de los mismos AR083044A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38674610P 2010-09-27 2010-09-27
US201161475280P 2011-04-14 2011-04-14
US201161515490P 2011-08-05 2011-08-05

Publications (1)

Publication Number Publication Date
AR083044A1 true AR083044A1 (es) 2013-01-30

Family

ID=45870888

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103412A AR083044A1 (es) 2010-09-27 2011-09-19 Anticuerpos anti-cd48 y usos de los mismos

Country Status (18)

Country Link
US (1) US9228014B2 (es)
EP (1) EP2621952A1 (es)
JP (2) JP6096117B2 (es)
KR (1) KR20140014067A (es)
CN (1) CN103261226B (es)
AR (1) AR083044A1 (es)
AU (1) AU2011312623B2 (es)
BR (1) BR112013007314A2 (es)
CA (1) CA2812748A1 (es)
CL (1) CL2013000843A1 (es)
EA (1) EA030437B1 (es)
IL (1) IL225484A (es)
MX (1) MX348417B (es)
MY (1) MY165273A (es)
NZ (1) NZ608660A (es)
SG (1) SG189089A1 (es)
TW (1) TWI507416B (es)
WO (1) WO2012047567A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
EP3578201B1 (en) 2012-06-28 2023-04-19 University Of Central Florida Research Foundation Incorporated Methods and compositions for natural killer cells
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10435463B2 (en) * 2014-09-05 2019-10-08 Academisch Medisch Centrum Hepatitis C virus specific antibody
BR112017019617A2 (pt) * 2015-03-18 2018-05-22 Seattle Genetics, Inc. Anticorpo, composto conjugado anticorpo- fármaco anti-cd48, composição de conjugado anticorpo-fármaco, métodos para tratar um paciente com um câncer que expressa cd48, para produzir um anticorpo anti-cd48 e para produzir um conjugado anticorpo-fármaco anti-cd48, ácido nucléico isolado, vetor isolado, e, célula hospedeira isolada
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP6805884B2 (ja) 2017-02-28 2020-12-23 住友ゴム工業株式会社 二輪自動用空気入りタイヤ
SG11201912548XA (en) 2017-07-06 2020-01-30 Regeneron Pharma Cell culture process for making a glycoprotein
EP3727629A1 (en) 2017-12-22 2020-10-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
EA202091689A1 (ru) 2018-01-31 2020-10-22 Ридженерон Фармасьютикалз, Инк. Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
WO2019168774A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
IL307577A (en) 2018-03-19 2023-12-01 Regeneron Pharma In-house capillary electrophoresis tests and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
BR112020024296A2 (pt) 2018-08-27 2021-03-09 Regeneron Pharmaceuticals, Inc. Métodos para produção de um intermediário de purificação de proteína concentrado, para monitoramento e controle dos atributos de qualidade críticos em um intermediário de purificação de proteína e para monitorar e controlar os níveis de excipientes no fluido de cultura de células colhido e/ou intermediário de purificação de proteína, e, intermediário de purificação de proteína
EA202190032A1 (ru) 2018-08-30 2021-03-12 Ридженерон Фармасьютикалз, Инк. Способы определения характеристик белковых комплексов
ES2942024T3 (es) 2019-01-16 2023-05-29 Regeneron Pharma Métodos para caracterizar enlaces disulfuro
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CA3216345A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
CA3158119A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
BR112022014212B1 (pt) 2020-01-21 2024-01-23 Regeneron Pharmaceuticals, Inc Métodos de análise de uma amostra incluindo uma proteína de interesse
US20210380696A1 (en) 2020-05-26 2021-12-09 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
AU2021332355A1 (en) 2020-08-31 2023-03-23 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
JP2023549925A (ja) * 2020-11-24 2023-11-29 ノバルティス アーゲー 抗ｃｄ４８抗体、抗体薬物コンジュゲート及びその使用
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
US20220257707A1 (en) 2020-12-17 2022-08-18 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
AU2022209730A1 (en) 2021-01-20 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
BR112023018665A2 (pt) 2021-03-26 2023-10-03 Regeneron Pharma Métodos e sistemas para desenvolvimento de protocolos de mistura
TW202314240A (zh) 2021-06-01 2023-04-01 美商再生元醫藥公司 微晶片毛細管電泳分析及試劑
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
TW202346856A (zh) 2022-03-18 2023-12-01 美商里珍納龍藥品有限公司 分析多肽變體的方法及系統

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692405A (en) 1985-03-05 1987-09-08 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to antigen on activated human B-cells and assay therefor, protein antigenic determinant therefor and method of making same
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
CA2249998A1 (en) 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
JPWO2005094886A1 (ja) 2004-03-31 2008-02-14 キリンファーマ株式会社 Ｇｐｉアンカー蛋白質アゴニストによる調節性ｔ細胞分化誘導・増殖方法およびそのための医薬組成物
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8409565B2 (en) * 2006-02-14 2013-04-02 Francesca Levi-Schaffer Therapeutic target and diagnostic marker for asthma and related conditions
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
WO2010117059A1 (ja) 2009-04-10 2010-10-14 国立大学法人大阪大学 形質細胞の腫瘍性増殖をきたす疾患の治療薬

Also Published As

Publication number Publication date
AU2011312623A1 (en) 2013-05-02
WO2012047567A1 (en) 2012-04-12
BR112013007314A2 (pt) 2017-03-21
CN103261226B (zh) 2016-06-15
JP2013542194A (ja) 2013-11-21
MX348417B (es) 2017-06-12
US20120076790A1 (en) 2012-03-29
EP2621952A1 (en) 2013-08-07
CL2013000843A1 (es) 2014-03-07
JP2017036324A (ja) 2017-02-16
MX2013003468A (es) 2013-05-31
KR20140014067A (ko) 2014-02-05
IL225484A (en) 2017-07-31
TW201305206A (zh) 2013-02-01
EA201370081A1 (ru) 2013-12-30
EA030437B1 (ru) 2018-08-31
SG189089A1 (en) 2013-05-31
IL225484A0 (en) 2013-06-27
TWI507416B (zh) 2015-11-11
NZ608660A (en) 2015-03-27
CN103261226A (zh) 2013-08-21
MY165273A (en) 2018-03-20
AU2011312623B2 (en) 2016-12-15
JP6096117B2 (ja) 2017-03-15
CA2812748A1 (en) 2012-04-12
US9228014B2 (en) 2016-01-05

Similar Documents

Publication Publication Date Title
AR083044A1 (es) Anticuerpos anti-cd48 y usos de los mismos
NI201200014A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana
UY34988A (es) Anticuerpos humanos para gfr alfa 3 y métodos para su uso
AR091305A1 (es) ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112015023557A2 (pt) proteínas de ligações dual específicas direcionadas contra tnfa
ECSP12011879A (es) Anticuerpo anti-tslp modificado por técnicas de ingeniería genética
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
AR078346A1 (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
UY33202A (es) Proteínas de unión a cd127
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
BR112013023513A2 (pt) anticorpos que ligam tgf-alfa e epiregulina
ECSP13012523A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33631A (es) Anticuerpos anti-cd48 y usos de los mismos
AR115423A2 (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
AR095235A1 (es) Anticuerpos dirigidos contra il-33 y sus usos

Legal Events

Date Code Title Description
FB Suspension of granting procedure